Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2019 | Nov. 07, 2019 | |
Document Information [Line Items] | ||
Entity Registrant Name | BIOLIFE SOLUTIONS INC | |
Entity Central Index Key | 0000834365 | |
Trading Symbol | blfs | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 20,452,205 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false | |
Title of 12(b) Security | Common Stock |
Consolidated Balance Sheets (Cu
Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2019 | Dec. 31, 2018 |
Current assets | ||
Cash and cash equivalents | $ 21,205,000 | $ 30,657,000 |
Accounts receivable, trade, net of allowance for doubtful accounts of $68 and $0 at September 30, 2019 and December 31, 2018, respectively | 4,313,000 | 3,045,000 |
Inventories | 5,694,000 | 3,509,000 |
Prepaid expenses and other current assets | 855,000 | 353,000 |
Total current assets | 32,067,000 | 37,564,000 |
Property and equipment | ||
Leasehold improvements | 1,599,000 | 1,284,000 |
Furniture and computer equipment | 588,000 | 706,000 |
Manufacturing and other equipment | 2,247,000 | 1,657,000 |
Subtotal | 4,434,000 | 3,647,000 |
Less: Accumulated depreciation | (2,298,000) | (2,328,000) |
Net property and equipment | 2,136,000 | 1,319,000 |
Assets held for rent, net | 2,976,000 | |
Operating lease right-of-use assets | 1,177,000 | |
Investments | 1,000,000 | 6,548,000 |
Intangible assets, net | 16,485,000 | |
Goodwill | 28,351,000 | |
Long-term deposits | 36,000 | 36,000 |
Total assets | 84,228,000 | 45,467,000 |
Current liabilities | ||
Accounts payable | 1,570,000 | 720,000 |
Accrued expenses and other current liabilities | 642,000 | 91,000 |
Accrued compensation | 1,576,000 | 998,000 |
Lease liability - operating, current portion | 771,000 | |
Lease liability – financing, current portion | 14,000 | |
Deferred rent, current portion | 130,000 | |
Contingent consideration - current | 371,000 | |
Total current liabilities | 4,944,000 | 1,939,000 |
Deferred rent, long-term | 349,000 | |
Long-term lease liability - operating | 753,000 | |
Long-term lease liability - financing | 6,000 | |
Other long-term liabilities | 3,000 | 31,000 |
Contingent consideration – long-term | 1,560,000 | |
Total liabilities | 7,266,000 | 2,319,000 |
Commitments and Contingencies (Note 11) | ||
Shareholders’ equity | ||
Common stock, $0.001 par value; 150,000,000 shares authorized, 20,344,825 and 18,547,406 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively | 20,000 | 19,000 |
Additional paid-in capital | 137,392,000 | 114,160,000 |
Accumulated deficit | (60,450,000) | (71,031,000) |
Total shareholders’ equity | 76,962,000 | 43,148,000 |
Total liabilities and shareholders’ equity | $ 84,228,000 | $ 45,467,000 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Accounts receivable, allowance for doubtful accounts | $ 68 | $ 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 150,000,000 | 150,000,000 |
Common stock, issued (in shares) | 20,344,825 | 18,547,406 |
Common stock, outstanding (in shares) | 20,344,825 | 18,547,406 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Revenue | $ 6,604 | $ 5,293 | $ 19,075 | $ 14,286 |
Cost of revenue | 2,084 | 1,606 | 5,690 | 4,507 |
Gross profit | 4,520 | 3,687 | 13,385 | 9,779 |
Operating expenses | ||||
Research and development | 1,309 | 312 | 2,420 | 983 |
Sales and marketing | 1,259 | 725 | 3,035 | 1,978 |
General and administrative | 2,258 | 1,455 | 6,579 | 4,199 |
Acquisition costs | 291 | 538 | ||
Total operating expenses | 5,117 | 2,492 | 12,572 | 7,160 |
Operating income (loss) | (597) | 1,195 | 813 | 2,619 |
Other income (expenses), net | ||||
Interest income | 110 | 80 | 417 | 121 |
Interest expense | (1) | (1) | (5) | (4) |
Loss on Disposal of Assets | (13) | (13) | ||
Loss from equity-method investment in SAVSU | (291) | (43) | (739) | (363) |
Gain on Acquisition of SAVSU | 10,108 | 10,108 | ||
Total other income (expenses), net | 9,913 | 36 | 9,768 | (246) |
Income before provision for income taxes | 9,316 | 1,231 | 10,581 | 2,373 |
Income taxes | ||||
Net income | 9,316 | 1,231 | 10,581 | 2,373 |
Less: Preferred stock dividends | (80) | (279) | ||
Net income attributable to common stockholders | $ 9,316 | $ 1,151 | $ 10,581 | $ 2,094 |
Basic net income per common share (in dollars per share) | $ 0.47 | $ 0.07 | $ 0.55 | $ 0.13 |
Diluted net income per common share (in dollars per share) | $ 0.37 | $ 0.05 | $ 0.43 | $ 0.10 |
Basic shares used to compute earnings per share (in shares) | 19,735,364 | 17,273,412 | 19,071,722 | 15,529,026 |
Diluted shares used to compute earnings per share (in shares) | 25,343,112 | 23,656,633 | 24,705,424 | 21,051,219 |
Consolidated Statements of Shar
Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands | Preferred Stock [Member]Series A Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2017 | 4,250 | 14,021,422 | |||
Balance at Dec. 31, 2017 | $ 14 | $ 84,036 | $ (73,958) | $ 10,092 | |
Stock based compensation | 1,131 | 1,131 | |||
Stock option/warrant exercises (in shares) | 2,684,899 | ||||
Stock option/warrant exercises | $ 3 | 11,721 | 11,724 | ||
Stock issued – on vested RSUs (in shares) | 96,594 | ||||
Stock issued – on vested RSUs | |||||
Net income | 2,373 | 2,373 | |||
Series A preferred stock redemption (in shares) | (1,063) | ||||
Series A preferred stock redemption | (1,063) | (1,063) | |||
Stock Issued for Private Equity Transaction – Casdin Capital, net of legal fees of $85,000 (in shares) | 1,428,571 | ||||
Stock Issued for Private Equity Transaction – Casdin Capital, net of legal fees of $85,000 | $ 1 | 19,914 | 19,915 | ||
Stock issued for services (in shares) | 5,939 | ||||
Stock issued for services | 36 | 36 | |||
Preferred stock dividends | (279) | (279) | |||
Balance (in shares) at Sep. 30, 2018 | 3,187 | 18,237,425 | |||
Balance at Sep. 30, 2018 | $ 18 | 115,775 | (71,864) | 43,929 | |
Balance (in shares) at Jun. 30, 2018 | 3,187 | 16,107,505 | |||
Balance at Jun. 30, 2018 | $ 16 | 92,654 | (73,015) | 19,655 | |
Stock based compensation | 383 | 383 | |||
Stock option/warrant exercises (in shares) | 681,294 | ||||
Stock option/warrant exercises | $ 1 | 2,824 | 2,825 | ||
Stock issued – on vested RSUs (in shares) | 20,055 | ||||
Stock issued – on vested RSUs | |||||
Net income | 1,231 | 1,231 | |||
Stock Issued for Private Equity Transaction – Casdin Capital, net of legal fees of $85,000 (in shares) | 1,428,571 | ||||
Stock Issued for Private Equity Transaction – Casdin Capital, net of legal fees of $85,000 | $ 1 | 19,914 | 19,915 | ||
Preferred stock dividends | (80) | (80) | |||
Balance (in shares) at Sep. 30, 2018 | 3,187 | 18,237,425 | |||
Balance at Sep. 30, 2018 | $ 18 | 115,775 | (71,864) | 43,929 | |
Balance (in shares) at Dec. 31, 2018 | 18,547,406 | ||||
Balance at Dec. 31, 2018 | $ 19 | 114,160 | (71,031) | 43,148 | |
Stock based compensation | 1,907 | 1,907 | |||
Shares Issued as consideration in SAVSU Acquisition (in shares) | 1,100,000 | ||||
Shares Issued as consideration in SAVSU Acquisition | $ 1 | 19,931 | 19,932 | ||
Stock option/warrant exercises (in shares) | 590,737 | ||||
Stock option/warrant exercises | 1,394 | 1,394 | |||
Stock issued – on vested RSUs (in shares) | 106,682 | ||||
Stock issued – on vested RSUs | |||||
Net income | 10,581 | 10,581 | |||
Balance (in shares) at Sep. 30, 2019 | 20,344,825 | ||||
Balance at Sep. 30, 2019 | $ 20 | 137,392 | (60,450) | 76,962 | |
Balance (in shares) at Jun. 30, 2019 | 18,898,609 | ||||
Balance at Jun. 30, 2019 | $ 19 | 116,013 | (69,766) | 46,266 | |
Stock based compensation | 654 | 654 | |||
Shares Issued as consideration in SAVSU Acquisition (in shares) | 1,100,000 | ||||
Shares Issued as consideration in SAVSU Acquisition | $ 1 | 19,931 | 19,932 | ||
Stock option/warrant exercises (in shares) | 325,676 | ||||
Stock option/warrant exercises | 794 | 794 | |||
Stock issued – on vested RSUs (in shares) | 20,540 | ||||
Stock issued – on vested RSUs | |||||
Net income | 9,316 | 9,316 | |||
Balance (in shares) at Sep. 30, 2019 | 20,344,825 | ||||
Balance at Sep. 30, 2019 | $ 20 | $ 137,392 | $ (60,450) | $ 76,962 |
Consolidated Statements of Sh_2
Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2018 | Sep. 30, 2018 | |
Additional Paid-in Capital [Member] | ||
Issuance fees | $ 85 | $ 85 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Cash flows from operating activities | ||
Net income | $ 10,581,000 | $ 2,373,000 |
Adjustments to reconcile net income to net cash provided by operating activities | ||
Depreciation | 373,000 | 245,000 |
Loss on disposal of property and equipment | 13,000 | |
Stock-based compensation expense | 1,907,000 | 1,131,000 |
Amortization of deferred rent related to lease incentives | 0 | (95,000) |
Amortization of operating lease liability | (132,000) | |
Interest expense – finance type lease | 2,000 | |
Loss from equity method investment in SAVSU | 739,000 | 363,000 |
Gain on acquisition of SAVSU | (10,108,000) | |
Amortization of intangible assets | 465,000 | |
Change in operating assets and liabilities | ||
Accounts receivable, trade | (372,000) | (1,678,000) |
Inventories | (1,730,000) | (1,064,000) |
Prepaid expenses and other current assets | (272,000) | (49,000) |
Other assets, net | (87,000) | |
Accounts payable | 377,000 | 343,000 |
Accrued compensation and other current liabilities | 558,000 | 205,000 |
Other liabilities | (98,000) | (11,000) |
Net cash provided by operating activities | 2,216,000 | 1,763,000 |
Cash flows from investing activities | ||
Investment in iVexSol | (1,000,000) | |
Investment in SAVSU | (6,000,000) | |
Purchase of property and equipment | (356,000) | (339,000) |
Purchase of Assets Held for Rent | (453,000) | |
Net cash used in investing activities | (12,997,000) | (6,339,000) |
Cash flows from financing activities | ||
Proceeds from private equity transaction | 20,000,000 | |
Payment of costs related to Stock Issuances | (44,000) | (43,000) |
Payments on equipment loan | (12,000) | (8,000) |
Payments on finance lease obligations | (9,000) | (10,000) |
Proceeds from exercise of common stock options and warrants | 1,394,000 | 11,724,000 |
Payments of preferred stock dividends | (306,000) | |
Payments for redemption of preferred stock | (1,063,000) | |
Net cash provided by financing activities | 1,329,000 | 30,294,000 |
Net increase (decrease) in cash and cash equivalents | (9,452,000) | 25,718,000 |
Cash and cash equivalents - beginning of period | 30,657,000 | 6,663,000 |
Cash and cash equivalents - end of period | 21,205,000 | 32,381,000 |
Non-cash investing and financing activities | ||
Series A preferred stock dividends accrued not yet paid | 80,000 | |
Stock issued for services provided in prior period included in liabilities at year-end | 36,000 | |
Receivables converted to equity investment in SAVSU | 150,000 | |
Purchase of equipment with debt | 18,000 | |
Purchase of property and equipment not yet paid | 146,000 | 49,000 |
Financing costs not yet paid | 53,000 | |
Stock Issued as consideration to acquire SAVSU | 19,932,000 | |
SAVSU [Member] | ||
Adjustments to reconcile net income to net cash provided by operating activities | ||
Gain on acquisition of SAVSU | (10,100,000) | |
Cash flows from investing activities | ||
Cash acquired on acquisition of SAVSU | 1,251,000 | |
Astero [Member] | ||
Cash flows from investing activities | ||
Payments related to the Astero Bio Acquisition, net of cash acquired | $ (12,439,000) |
Note 1 - Organization and Signi
Note 1 - Organization and Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Basis of Presentation and Significant Accounting Policies [Text Block] | 1. Organization and Significant Accounting Policies Business BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is a leading developer, manufacturer and supplier of a portfolio of bioproduction tools including; proprietary biopreservation media and automated thawing products for cell and gene therapies. Our CryoStor ® ® ® 56% not August 2019, Basis of Presentation We have prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not may 10 December 31, 2018 Changes in Significant Accounting Policies The following significant accounting policies have been added or updated since our Annual Report on Form 10 December 31, 2018. Business Combinations The Company’s identifiable assets acquired and liabilities assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models The Company’s estimates of fair value are based upon assumptions it believes to be reasonable, but that are inherently uncertain and unpredictable. Assumptions may may Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period, with any change in the value recorded as other income or expense. During the measurement period, which may one Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not fourth may first not 350. not 50 not not not not September 30, 2019, no Intangible Assets Intangible assets consist of developed technology, customer relationships, and tradenames and trademarks, resulting from the Company’s acquisitions. Intangible assets are recorded at fair value on the date of acquisition and amortized over their estimated useful lives on a straight-line basis. Assets held for rent Assets held for rent consist of SAVSU shippers and related components in production, shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Our customers rent the shippers under a rental agreement. We retain the right to the shippers and the evo tracking software platform. At the end of the rental agreement, the customer returns the shipper to the Company. When the shipper is sent to our customers, we deprecate the cost of the shippers over its estimated useful life of three Revenue We account for revenue related to the rental of SAVSU shippers under the accounting standard for leases as the customer has the right to use the asset over a period of time under a rental agreement. We record revenue ratably over the rental term. Significant Accounting Policies Update In February 2016, No. 2016 02, 842 2016 02” 2016 02. We adopted ASU 2016 02 842 January 1, 2019 not January 1, 2019 840, January 1, 2019. The adoption of this standard resulted in the recording of operating lease right-of-use assets of $1.3 $1.8 January 1, 2019. $0.5 842. 842 not no Principles of Consolidation The consolidated financial statements for the three nine September 30, 2019 April 1, 2019, August 8, 2019, April 1, 2019 August 8, 2019, three nine September 30, 2018 December 31, 2018, Investments Investments at September 30, 2019, $1.0 $1.0 Equity Method Investments Investments at December 31, 2018, August 8, 2019. not 20% 50%, three nine September 30, 2019, $0.7 $1.7 $0.3 $0.7 three nine September 30, 2018, $16,000 $1.1 $43,000 $0.4 Concentrations of credit risk and business risk In the three September 30, 2019, 33% three nine September 30, 2019, 17% one three September 30, 2018, 41% three nine September 30, 2018, 28% two No 10% three nine September 30, 2019 2018. three September 30, 2019 2018, 81% 90%, nine September 30, 2019 2018, 84% 88%, September 30, 2019, one 11% December 31, 2018, three 71% Revenue from customers located in Canada represented 12% 17% 11% 14% three nine September 30, 2019, 15% 13% 8% 10% three nine September 30, 2018, Recent Accounting Pronouncements There have been no not |
Note 2 - Fair Value Measurement
Note 2 - Fair Value Measurement | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 2. Fair Value Measurement In accordance with FASB ASC Topic 820, 820” 820 820 three Level 1 Level 2 1 not Level 3 As of September 30, 2019, December 31, 2018, not The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of September 30, 2019 December 31, 2018, three As of September 30, 2019 Level 1 Level 2 Level 3 Total Assets: Total cash and cash equivalents $ 21,205 $ — $ — $ 21,205 Liabilities: Contingent consideration - business combinations $ — $ — $ 1,931 $ 1,931 As of December 31, 2018 Level 1 Level 2 Total Total cash and cash equivalents $ 30,657 $ — $ 30,657 The fair values of cash and cash equivalents classified as Level 1 3 no September 30, 2019, three nine September 30, 2019. no 2 3 not 1 2 nine September 30, 2019 twelve December 31, 2018. |
Note 3 - Business Combinations
Note 3 - Business Combinations | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Business Combination Disclosure [Text Block] | 3. Business Combinations On August 8, 2019, 8,616 56% not 1,100,000 August 8, 2019, Please see footnote 3 10 June 30, 2019 Consideration transferred The SAVSU acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, 56% 1,100,000 $18.12 $19.9 100% $35.8 $5.8 $15.9 44% 56% not $10.1 Under the acquisition method of accounting, the assets acquired and liabilities assumed from SAVSU were recorded as of the acquisition date, at their respective fair values, and consolidated with those of BioLife. The fair value of the net tangible assets acquired is estimated to be approximately $4.6 $12.4 $18.8 not may Total consideration recorded for the acquisition of SAVSU is as follows (amounts in thousands): Stock consideration for 55.6% equity interest purchased $ 19,932 This stock consideration plus the fair value of our existing equity investment in SAVSU of $15.9 $35.8 not $ 116,000 three nine September 30, 2019. Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their estimated fair values (amounts in thousands). We may third one August 7, 2019. Cash and cash equivalents $ 1,251 Accounts receivable, net 741 Prepaid expenses and other current assets 33 Property, plant and equipment 704 Operating lease right-of-use asset 232 Assets held for lease 2,575 Customer relationships 80 Tradenames 1,320 Developed technology 11,000 Goodwill 18,826 Accounts Payable (77 ) Other liabilities (836 ) Fair value of net assets acquired $ 35,849 The fair value of SAVSU’s identifiable intangible assets and estimated useful lives have been preliminary estimated as follows (amounts in thousands): Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 80 6 Tradenames 1,320 9 Developed technologies 11,000 7 – 8 Total identifiable intangible assets $ 12,400 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not These preliminary estimates of fair value and estimated useful lives may Acquired Goodwill The goodwill of $18.8 not Revenue, Net Income and Pro Forma Presentation The Company recorded revenue from SAVSU of $ 211,000 $ 676,000 three nine September 30, 2019. August 8, 2019 April 1, 2019, January 1, 2018 nine September 30, 2019 2018 $1.0 $1.5 $17.0 $147,000 $396,000, $116,000 $210,000, $538,000 $155,000 $10.1 nine September 30, 2019. not not January 1, 2018 (Unaudited) Nine Months Ended September 30, (In thousands) 2019 2018 Total revenue $ 19,941 $ 14,861 Net loss attributable to common stockholders $ (1,322 ) $ (1,495 ) Earnings/(loss) per share: Basic $ (0.07 ) $ (0.10 ) |
Note 4 - Inventory
Note 4 - Inventory | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 4. Inventory Inventory consists of the following at September 30, 2019 December 31, 2018: (In thousands) September 30, 2019 December 31, 2018 Raw materials $ 1,343 $ 1,453 Work in progress 887 652 Finished goods 3,464 1,404 Total $ 5,694 $ 3,509 |
Note 5 - Assets Held for Rent
Note 5 - Assets Held for Rent | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Assets Held For Rent [Text Block] | 5. Assets held for rent Assets held for rent consist of the following at September 30, 2019: (In thousands) September 30, 2019 Shippers placed in service $ 1,577 Accumulated deprecation (51 ) Net 1,526 Shippers and related components in production 1,450 Total $ 2,976 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. |
Note 6 - Deferred Rent
Note 6 - Deferred Rent | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Deferred Rent [Text Block] | 6 . Deferred Rent Deferred rent consists of the following at December 31, 2018. January 1, 2019 2016 02 13 (In thousands) December 31, 2018 Landlord-funded leasehold improvements $ 1,125 Less accumulated amortization (757 ) Total 368 Straight line rent adjustment 111 Total deferred rent $ 479 During the three nine September 30, 2019, no three nine September 30, 2018, $32,000 $95,000, Straight line rent adjustment for the three nine September 30, 2018 |
Note 7 - Share-based Compensati
Note 7 - Share-based Compensation | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 7 . Share-based Compensation Service Vesting-Based Stock Options The following is a summary of service vesting-based stock option activity for the nine September 30, 2019 September 30, 2019: Nine Month Period Ended September 30, 2019 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 2,043,402 $ 1.91 Granted — $ — Exercised (339,237 ) $ 1.83 Forfeited (3,437 ) $ 5.69 Expired — $ — Outstanding service vesting-based at September 30, 2019 1,700,728 $ 1.92 Service vesting-based options exercisable at September 30, 2019 1,546,830 $ 1.89 We recognized stock compensation expense related to service vesting-based options of $65,000 $147,000 three September 30, 2019 2018, $305,000 $449,000 nine September 30, 2019 September 30, 2018, September 30, 2019, $25.0 $22.8 September 30, 2019. three September 30, 2019 2018 $1.7 $2.1 nine September 30, 2019 2018 $5.2 $3.1 no nine September 30, 2019 2018. September 30, 2019 5.1 5.1 September 30, 2019 $213,000 1.2 Performance-based Stock Options The Company’s Board of Directors implemented a Management Performance Bonus Plan for 2017. December 31, 2017, 1,000,000 $1.64, 2017 50% 2017, 50% one not no February 27, 2018, 2017 999,997 50% March 8, 2018 50% March 8, 2019. The following is a summary of performance-based stock option activity for the nine September 30, 2019, September 30, 2019: Nine Month Period Ended September 30, 2019 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 964,997 $ 1.64 Granted — $ — Exercised (135,000 ) $ 1.64 Outstanding performance-based at September 30, 2019 829,997 $ 1.64 Performance-based options exercisable at September 30, 2019 829,997 $ 1.64 We recognized stock compensation expense related to performance-based options of none $128,000 three September 30, 2019 2018, none $381,000 nine September 30, 2019 2018. September 30, 2019, $12.4 September 30, 2019. three nine September 30, 2019 $ 2.3 three nine September 30, 2018 none $285,000, September 30, 2019, 2.2 September 30, 2019 There were no three nine September 30, 2019 2018. Restricted Stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the nine September 30, 2019, September 30, 2019: Nine Month Period Ended September 30, 2019 Service vesting-based restricted stock Number of Grant-Date Outstanding at beginning of year 279,919 $ 5.00 Granted 224,218 $ 17.68 Vested (106,683 ) $ 4.65 Forfeited (26,354 ) $ 11.60 Outstanding at September 30, 2019 371,100 $ 12.29 The aggregate fair value of the service vesting-based awards granted during the three September 30, 2019 2018 $802,000 $148,000, nine September 30, 2019 2018 $4.0 $1.3 three September 30, 2019 2018 $368,000 $393,000, nine September 30, 2019 2018 $1.6 $874,000, We recognized stock compensation expense of $303,000 $108,000 three September 30, 2019 2018, $777,000 $301,000 nine September 30, 2019 2018, September 30, 2019, $4.0 3.3 Performance-based restricted stock In 2019, 94,247 four 94,247 0% 200% January 1, 2019 December 31, 2020 20 94,247 50th may 188,494 80th no 30th 29,604 April 1, 2019 two Nine Month Period Ended September 30, 2019 Performance-based restricted stock Number of Grant-Date Outstanding at beginning of year — $ — Expected to vest 123,851 $ 17.79 Vested — $ — Outstanding at September 30, 2019 123,851 $ 17.79 For the period ended September 30, 2019, $2.2 $286,000 $825,000 three nine September 30, 2019, September 30, 2019, $1.4 1.3 Total Stock Compensation Expense We recorded total stock compensation expense for the three nine September 30, 2019 2018, Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2019 2018 2019 2018 Research and development costs $ 122 $ 65 $ 327 $ 195 Sales and marketing costs 141 64 438 202 General and administrative costs 338 195 1,016 577 Cost of revenue 53 59 126 157 Total $ 654 $ 383 $ 1,907 $ 1,131 |
Note 8 - Warrants
Note 8 - Warrants | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Warrants [Text Block] | 8 . Warrants At September 30, 2019 December 31, 2018, 3,963,505 4,080,005 $4.33 $4.35, three nine September 30, 2019, 87,500 116,500 $4.75, $416,000 $553,000, March 2021 May 2021. |
Note 9 - Income Taxes
Note 9 - Income Taxes | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 9 . Income Taxes We have recorded a full valuation allowance against our deferred tax assets. As we continue to have multiple quarters of positive net income, we will assess our valuation allowance. Based on all available evidence, we determined that we have not September 30, 2019. may |
Note 10 - Net Income Per Common
Note 10 - Net Income Per Common Share | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 10 . Net Income per Common Share Basic earnings per share is calculated by dividing the net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding as determined by the treasury method during the period. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. For the three nine September 30, 2019 2018, The following table shows the calculation of basic and diluted earnings per shares: Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands, except per share and share data) 2019 2018 2019 2018 Numerator: Net income attributable to common stockholders $ 9,316 $ 1,151 $ 10,581 $ 2,094 Denominator: Weighted average basic shares outstanding 19,735,364 17,273,412 19,071,722 15,529,026 Effect of dilutive securities 5,607,748 6,383,221 5,633,702 5,522,193 Weighted average diluted shares 25,343,112 23,656,633 24,705,424 21,051,219 Basic earnings per share $ 0.47 $ 0.07 $ 0.55 $ 0.13 Diluted earnings per share $ 0.37 $ 0.05 $ 0.43 $ 0.10 |
Note 11 - Commitments & Conting
Note 11 - Commitments & Contingencies | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 1 1 . Commitments & Contingencies Employment Agreements We have employment agreements with our Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice President of Operations, Vice President of Marketing, Vice President of Sales – Thaw Technologies, Vice President of Product Development – Thaw Technologies, Senior Vice President of Cold Chain Technologies, Vice President of Sales, evo platform and Vice President of Sales. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none |
Note 12 - Revenue
Note 12 - Revenue | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | 1 2 . Revenue We currently operate as one The following table disaggregates revenue by market segment and distributors: Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2019 2018 2019 2018 Net revenue: Regenerative medicine $ 3,421 $ 2,876 $ 9,567 $ 7,965 Distributors 2,613 1,887 7,943 4,621 Drug discovery 225 276 711 916 BioBanking 345 255 854 784 Total $ 6,604 $ 5,293 $ 19,075 $ 14,286 The following table disaggregates revenue by product category: Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2019 2018 2019 2018 Net revenue: Media $ 6,069 $ 5,293 $ 18,165 $ 14,286 Automated thawing products 324 — 699 — Cold chain shipping 211 — 211 — Total $ 6,604 $ 5,293 $ 19,075 $ 14,286 |
Note 13 - Leases
Note 13 - Leases | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Lessee, Leases [Text Block] | 1 3 . Leases Our operating leases are primarily related to our Bothell, Washington headquarters space lease and our Albuquerque, New Mexico SAVSU space lease. The term of our Bothell lease continues until July 31, 2021 two five first August 1, 2021, second first December 31, 2021. two three first December 1, 2021, second first not not 6.5%, 8.1%, 1.8 1.4 three September 30, 2019 $160,000 $204,000, nine September 30, 2019 $444,000 $576,000, Maturities of lease liabilities as of September 30, 2019 (In thousands) Operating Leases Financing Leases 2019 (less than one year) $ 201 $ 4 2020 868 15 2021 556 3 Total lease payments 1,625 22 Less: interest (101 ) (2 ) Total present value of lease liabilities $ 1,524 $ 20 |
Note 14 - Subsequent Event
Note 14 - Subsequent Event | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 1 4 . Subsequent Event On October 2, 2019, $1.5 18% On November 12, 2019, $15 $11 $4 $15 five Due to the limited time since the acquisition date and the effort required to assess the fair value of assets acquired and liabilities assumed, the initial accounting for the business combination is incomplete at the time of this filing. As a result, the Company is unable to provide the amounts recognized for the major classes of assets acquired and liabilities assumed, acquisition contingencies and goodwill. Also, the Company is unable to provide pro forma revenues and earnings of the combined entity. This information is expected to be included in the Company's Annual Report on Form 10 December 31, 2019. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation We have prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not may 10 December 31, 2018 Changes in Significant Accounting Policies The following significant accounting policies have been added or updated since our Annual Report on Form 10 December 31, 2018. Business Combinations The Company’s identifiable assets acquired and liabilities assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models The Company’s estimates of fair value are based upon assumptions it believes to be reasonable, but that are inherently uncertain and unpredictable. Assumptions may may Goodwill is calculated as the excess of the purchase price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period, with any change in the value recorded as other income or expense. During the measurement period, which may one Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not fourth may first not 350. not 50 not not not not September 30, 2019, no Intangible Assets Intangible assets consist of developed technology, customer relationships, and tradenames and trademarks, resulting from the Company’s acquisitions. Intangible assets are recorded at fair value on the date of acquisition and amortized over their estimated useful lives on a straight-line basis. Assets held for rent Assets held for rent consist of SAVSU shippers and related components in production, shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Our customers rent the shippers under a rental agreement. We retain the right to the shippers and the evo tracking software platform. At the end of the rental agreement, the customer returns the shipper to the Company. When the shipper is sent to our customers, we deprecate the cost of the shippers over its estimated useful life of three Revenue We account for revenue related to the rental of SAVSU shippers under the accounting standard for leases as the customer has the right to use the asset over a period of time under a rental agreement. We record revenue ratably over the rental term. Significant Accounting Policies Update In February 2016, No. 2016 02, 842 2016 02” 2016 02. We adopted ASU 2016 02 842 January 1, 2019 not January 1, 2019 840, January 1, 2019. The adoption of this standard resulted in the recording of operating lease right-of-use assets of $1.3 $1.8 January 1, 2019. $0.5 842. 842 not no |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation The consolidated financial statements for the three nine September 30, 2019 April 1, 2019, August 8, 2019, April 1, 2019 August 8, 2019, three nine September 30, 2018 December 31, 2018, |
Investment, Policy [Policy Text Block] | Investments Investments at September 30, 2019, $1.0 $1.0 |
Equity Method Investments [Policy Text Block] | Equity Method Investments Investments at December 31, 2018, August 8, 2019. not 20% 50%, three nine September 30, 2019, $0.7 $1.7 $0.3 $0.7 three nine September 30, 2018, $16,000 $1.1 $43,000 $0.4 |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentrations of credit risk and business risk In the three September 30, 2019, 33% three nine September 30, 2019, 17% one three September 30, 2018, 41% three nine September 30, 2018, 28% two No 10% three nine September 30, 2019 2018. three September 30, 2019 2018, 81% 90%, nine September 30, 2019 2018, 84% 88%, September 30, 2019, one 11% December 31, 2018, three 71% Revenue from customers located in Canada represented 12% 17% 11% 14% three nine September 30, 2019, 15% 13% 8% 10% three nine September 30, 2018, |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements There have been no not |
Note 2 - Fair Value Measureme_2
Note 2 - Fair Value Measurement (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | As of September 30, 2019 Level 1 Level 2 Level 3 Total Assets: Total cash and cash equivalents $ 21,205 $ — $ — $ 21,205 Liabilities: Contingent consideration - business combinations $ — $ — $ 1,931 $ 1,931 As of December 31, 2018 Level 1 Level 2 Total Total cash and cash equivalents $ 30,657 $ — $ 30,657 |
Note 3 - Business Combinations
Note 3 - Business Combinations (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | Stock consideration for 55.6% equity interest purchased $ 19,932 |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | Cash and cash equivalents $ 1,251 Accounts receivable, net 741 Prepaid expenses and other current assets 33 Property, plant and equipment 704 Operating lease right-of-use asset 232 Assets held for lease 2,575 Customer relationships 80 Tradenames 1,320 Developed technology 11,000 Goodwill 18,826 Accounts Payable (77 ) Other liabilities (836 ) Fair value of net assets acquired $ 35,849 |
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] | Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 80 6 Tradenames 1,320 9 Developed technologies 11,000 7 – 8 Total identifiable intangible assets $ 12,400 |
Business Acquisition, Pro Forma Information [Table Text Block] | (Unaudited) Nine Months Ended September 30, (In thousands) 2019 2018 Total revenue $ 19,941 $ 14,861 Net loss attributable to common stockholders $ (1,322 ) $ (1,495 ) Earnings/(loss) per share: Basic $ (0.07 ) $ (0.10 ) |
Note 4 - Inventory (Tables)
Note 4 - Inventory (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | (In thousands) September 30, 2019 December 31, 2018 Raw materials $ 1,343 $ 1,453 Work in progress 887 652 Finished goods 3,464 1,404 Total $ 5,694 $ 3,509 |
Note 5 - Assets Held for Rent (
Note 5 - Assets Held for Rent (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Scheduleof Assets Held for Rent [Table Text Block] | (In thousands) September 30, 2019 Shippers placed in service $ 1,577 Accumulated deprecation (51 ) Net 1,526 Shippers and related components in production 1,450 Total $ 2,976 |
Note 6 - Deferred Rent (Tables)
Note 6 - Deferred Rent (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Deferred Rent [Table Text Block] | (In thousands) December 31, 2018 Landlord-funded leasehold improvements $ 1,125 Less accumulated amortization (757 ) Total 368 Straight line rent adjustment 111 Total deferred rent $ 479 |
Note 7 - Share-based Compensa_2
Note 7 - Share-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Nine Month Period Ended September 30, 2019 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 2,043,402 $ 1.91 Granted — $ — Exercised (339,237 ) $ 1.83 Forfeited (3,437 ) $ 5.69 Expired — $ — Outstanding service vesting-based at September 30, 2019 1,700,728 $ 1.92 Service vesting-based options exercisable at September 30, 2019 1,546,830 $ 1.89 Nine Month Period Ended September 30, 2019 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 964,997 $ 1.64 Granted — $ — Exercised (135,000 ) $ 1.64 Outstanding performance-based at September 30, 2019 829,997 $ 1.64 Performance-based options exercisable at September 30, 2019 829,997 $ 1.64 |
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] | Nine Month Period Ended September 30, 2019 Service vesting-based restricted stock Number of Grant-Date Outstanding at beginning of year 279,919 $ 5.00 Granted 224,218 $ 17.68 Vested (106,683 ) $ 4.65 Forfeited (26,354 ) $ 11.60 Outstanding at September 30, 2019 371,100 $ 12.29 Nine Month Period Ended September 30, 2019 Performance-based restricted stock Number of Grant-Date Outstanding at beginning of year — $ — Expected to vest 123,851 $ 17.79 Vested — $ — Outstanding at September 30, 2019 123,851 $ 17.79 |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2019 2018 2019 2018 Research and development costs $ 122 $ 65 $ 327 $ 195 Sales and marketing costs 141 64 438 202 General and administrative costs 338 195 1,016 577 Cost of revenue 53 59 126 157 Total $ 654 $ 383 $ 1,907 $ 1,131 |
Note 10 - Net Income Per Comm_2
Note 10 - Net Income Per Common Share (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands, except per share and share data) 2019 2018 2019 2018 Numerator: Net income attributable to common stockholders $ 9,316 $ 1,151 $ 10,581 $ 2,094 Denominator: Weighted average basic shares outstanding 19,735,364 17,273,412 19,071,722 15,529,026 Effect of dilutive securities 5,607,748 6,383,221 5,633,702 5,522,193 Weighted average diluted shares 25,343,112 23,656,633 24,705,424 21,051,219 Basic earnings per share $ 0.47 $ 0.07 $ 0.55 $ 0.13 Diluted earnings per share $ 0.37 $ 0.05 $ 0.43 $ 0.10 |
Note 12 - Revenue (Tables)
Note 12 - Revenue (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2019 2018 2019 2018 Net revenue: Regenerative medicine $ 3,421 $ 2,876 $ 9,567 $ 7,965 Distributors 2,613 1,887 7,943 4,621 Drug discovery 225 276 711 916 BioBanking 345 255 854 784 Total $ 6,604 $ 5,293 $ 19,075 $ 14,286 Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2019 2018 2019 2018 Net revenue: Media $ 6,069 $ 5,293 $ 18,165 $ 14,286 Automated thawing products 324 — 699 — Cold chain shipping 211 — 211 — Total $ 6,604 $ 5,293 $ 19,075 $ 14,286 |
Note 13 - Leases (Tables)
Note 13 - Leases (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | (In thousands) Operating Leases Financing Leases 2019 (less than one year) $ 201 $ 4 2020 868 15 2021 556 3 Total lease payments 1,625 22 Less: interest (101 ) (2 ) Total present value of lease liabilities $ 1,524 $ 20 |
Note 1 - Organization and Sig_2
Note 1 - Organization and Significant Accounting Policies (Details Textual) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | Dec. 31, 2018USD ($) | Aug. 08, 2019 | Jan. 01, 2019USD ($) | |
Operating Lease, Right-of-Use Asset | $ 1,177,000 | $ 1,177,000 | $ 1,300,000 | ||||
Operating Lease, Liability, Total | 1,524,000 | 1,524,000 | $ 1,800,000 | ||||
Deferred Rent Credit | $ 479,000 | ||||||
Net Income (Loss) Attributable to Parent, Total | 9,316,000 | $ 1,231,000 | 10,581,000 | $ 2,373,000 | |||
Income (Loss) from Equity Method Investments, Total | $ (291,000) | $ (43,000) | $ (739,000) | $ (363,000) | |||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | |||||||
Concentration Risk, Percentage | 33.00% | 41.00% | 17.00% | 28.00% | |||
Number of Major Customers | 3 | 3 | 1 | 2 | |||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | CANADA | |||||||
Concentration Risk, Percentage | 12.00% | 15.00% | 17.00% | 13.00% | |||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member] | |||||||
Concentration Risk, Percentage | 11.00% | 8.00% | 14.00% | 10.00% | |||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | CryoStor Products [Member] | |||||||
Concentration Risk, Percentage | 81.00% | 90.00% | 84.00% | 88.00% | |||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | |||||||
Concentration Risk, Percentage | 11.00% | 71.00% | |||||
Number of Major Customers | 1 | 3 | |||||
SAVSU [Member] | |||||||
Income (Loss) from Equity Method Investments, Total | $ (300,000) | $ (43,000) | $ (700,000) | $ (400,000) | |||
SAVSU [Member] | |||||||
Net Income (Loss) Attributable to Parent, Total | (700,000) | $ (16,000) | (1,700,000) | $ (1,100,000) | |||
Convertible Debt Securities [Member] | |||||||
Debt Securities, Held-to-maturity, Total | $ 1,000,000 | $ 1,000,000 | |||||
SAVSU [Member] | |||||||
Business Acquisition, Percentage of Voting Interests Acquired | 55.60% |
Note 2 - Fair Value Measureme_3
Note 2 - Fair Value Measurement (Details Textual) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Financial and Nonfinancial Liabilities, Fair Value Disclosure | $ 0 | |
Fair Value, Inputs, Level 2 [Member] | ||
Assets, Fair Value Disclosure | $ 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Assets, Fair Value Disclosure | $ 0 | $ 0 |
Note 2 - Fair Value Measureme_4
Note 2 - Fair Value Measurement - Financial Assets on Recurring Basis (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Contingent consideration - business combinations | $ 0 | |
Fair Value, Inputs, Level 2 [Member] | ||
Total cash and cash equivalents | $ 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Total cash and cash equivalents | 0 | 0 |
Fair Value, Recurring [Member] | ||
Total cash and cash equivalents | 21,205 | 30,657 |
Contingent consideration - business combinations | 1,931 | |
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Total cash and cash equivalents | 21,205 | 30,657 |
Contingent consideration - business combinations | ||
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Total cash and cash equivalents | ||
Contingent consideration - business combinations | ||
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Total cash and cash equivalents | ||
Contingent consideration - business combinations | $ 1,931 |
Note 3 - Business Combination_2
Note 3 - Business Combinations (Details Textual) - USD ($) | Aug. 08, 2019 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 |
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 19,932,000 | |||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total | $ 10,108,000 | 10,108,000 | ||||
Goodwill, Ending Balance | 28,351,000 | 28,351,000 | ||||
Business Combination, Acquisition Related Costs | 291,000 | 538,000 | ||||
Amortization of Intangible Assets, Total | 465,000 | |||||
Share-based Payment Arrangement, Noncash Expense, Total | 1,907,000 | 1,131,000 | ||||
SAVSU [Member] | ||||||
Equity Method Investments | $ 5,800,000 | |||||
SAVSU [Member] | ||||||
Business Combinations, Number of Shares Acquired | 8,616 | |||||
Business Acquisition, Percentage of Voting Interests Acquired | 55.60% | |||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 1,100,000 | |||||
Share Price | $ 18.12 | |||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 19,932,000 | |||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 35,849,000 | |||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value | $ 15,900,000 | |||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage | 44.00% | |||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total | $ 10,100,000 | 10,100,000 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net | 4,600,000 | |||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 12,400,000 | |||||
Goodwill, Ending Balance | 18,826,000 | 18,800,000 | 18,800,000 | |||
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination, Total | $ 35,800,000 | |||||
Business Combination, Acquisition Related Costs | 116,000 | 116,000 | ||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 211,000 | 211,000 | ||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $ (676,000) | (676,000) | ||||
Finite-lived Intangible Assets Acquired | 17,000,000 | |||||
Acquisition-related Transaction Costs, Excluded from Pro Forma Net Income (Loss) | 538,000 | |||||
Purchase Accouning Adjustment to Inventory Exlcuded from Pro Forma Net Income (Loss) | 155,000 | |||||
SAVSU [Member] | Amortization Expense for Acquired Identifiable Intangible Assets [Member] | ||||||
Amortization of Intangible Assets, Total | 1,000,000 | 1,500,000 | ||||
SAVSU [Member] | Adjustment to Share-based Compensation [Member] | ||||||
Share-based Payment Arrangement, Noncash Expense, Total | 147,000 | 396,000 | ||||
SAVSU [Member] | Adjustments for Salary Increase With Acquisitions [Member] | ||||||
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold | $ 116,000 | $ 210,000 |
Note 3 - Business Combination_3
Note 3 - Business Combinations - Consideration (Details) - USD ($) $ in Thousands | Aug. 08, 2019 | Sep. 30, 2019 | Sep. 30, 2018 |
Stock consideration for 55.6% equity interest purchased | $ 19,932 | ||
SAVSU [Member] | |||
Stock consideration for 55.6% equity interest purchased | $ 19,932 |
Note 3 - Business Combination_4
Note 3 - Business Combinations - Consideration (Details) (Parentheticals) | Aug. 08, 2019 |
SAVSU [Member] | |
Percnetage equity interest purchased | 55.60% |
Note 3 - Business Combination_5
Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) - USD ($) | Sep. 30, 2019 | Aug. 08, 2019 | Dec. 31, 2018 |
Goodwill | $ 28,351,000 | ||
SAVSU [Member] | |||
Cash and cash equivalents | $ 1,251,000 | ||
Accounts receivable, net | 741,000 | ||
Prepaid expenses and other current assets | 33,000 | ||
Property, plant and equipment | 704,000 | ||
Operating lease right-of-use asset | 232,000 | ||
Assets held for lease | 2,575,000 | ||
Intangible assets | 12,400,000 | ||
Goodwill | $ 18,800,000 | 18,826,000 | |
Accounts Payable | 77,000 | ||
Other liabilities | 836,000 | ||
Fair value of net assets acquired | 35,849,000 | ||
SAVSU [Member] | Customer Relationships [Member] | |||
Intangible assets | 80,000 | ||
SAVSU [Member] | Trade Names [Member] | |||
Intangible assets | 1,320,000 | ||
SAVSU [Member] | Developed Technology Rights [Member] | |||
Intangible assets | $ 11,000,000 |
Note 3 - Business Combination_6
Note 3 - Business Combinations - Acquired Intangible Assets (Details) - SAVSU [Member] $ in Thousands | Aug. 08, 2019USD ($) |
Identifiable intangible assets | $ 12,400 |
Customer Relationships [Member] | |
Identifiable intangible assets | $ 80 |
Identifiable intangible assets useful life (Year) | 6 years |
Trade Names [Member] | |
Identifiable intangible assets | $ 1,320 |
Identifiable intangible assets useful life (Year) | 9 years |
Developed Technology Rights [Member] | |
Identifiable intangible assets | $ 11,000 |
Developed Technology Rights [Member] | Minimum [Member] | |
Identifiable intangible assets useful life (Year) | 7 years |
Developed Technology Rights [Member] | Maximum [Member] | |
Identifiable intangible assets useful life (Year) | 8 years |
Note 3 - Business Combination_7
Note 3 - Business Combinations - Pro Forma Information (Details) - SAVSU [Member] - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Total revenue | $ 19,941 | $ 14,861 |
Net loss attributable to common stockholders | $ (1,322) | $ (1,495) |
Basic (in dollars per share) | $ (0.07) | $ (0.10) |
Note 4 - Inventory - Summary of
Note 4 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Raw materials | $ 1,343 | $ 1,453 |
Work in progress | 887 | 652 |
Finished goods | 3,464 | 1,404 |
Total | $ 5,694 | $ 3,509 |
Note 5 - Assets Held for Rent -
Note 5 - Assets Held for Rent - Assets Held for Rent (Details) $ in Thousands | Sep. 30, 2019USD ($) |
Shippers placed in service | $ 1,577 |
Accumulated deprecation | (51) |
Net | 1,526 |
Shippers and related components in production | 1,450 |
Total | $ 2,976 |
Note 6 - Deferred Rent (Details
Note 6 - Deferred Rent (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Amortization of Deferred Rent | $ 0 | $ 32,000 | $ 0 | $ 95,000 |
Note 6 - Deferred Rent - Summar
Note 6 - Deferred Rent - Summary of Deferred Rent (Details) $ in Thousands | Dec. 31, 2018USD ($) |
Landlord-funded leasehold improvements | $ 1,125 |
Less accumulated amortization | (757) |
Total | 368 |
Straight line rent adjustment | 111 |
Total deferred rent | $ 479 |
Note 7 - Share-based Compensa_3
Note 7 - Share-based Compensation (Details Textual) - USD ($) | Apr. 01, 2019 | Feb. 27, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2017 |
Share-based Payment Arrangement, Expense | $ 654,000 | $ 383,000 | $ 1,907,000 | $ 1,131,000 | |||
Share-based Payment Arrangement, Option [Member] | |||||||
Share-based Payment Arrangement, Expense | 65,000 | 147,000 | 305,000 | 449,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | 25,000,000 | 25,000,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | 22,800,000 | 22,800,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | 1,700,000 | 2,100,000 | $ 5,200,000 | $ 3,100,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 0 | 0 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 5 years 36 days | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | 5 years 36 days | ||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 213,000 | $ 213,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 1 year 73 days | ||||||
Performance Shares [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | |||||||
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | |||||||
Share-based Payment Arrangement, Expense | 0 | 128,000 | $ 0 | $ 381,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | 12,400,000 | 12,400,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 2,300,000 | $ 0 | $ 2,300,000 | $ 285,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 0 | 0 | 0 | 0 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | 2 years 73 days | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 1,000,000 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ 1.64 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 999,997 | ||||||
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting on Release of Audited Financial Statements for 2017 [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | 50.00% | ||||||
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting One Year After Release of Audited Financial Statements for 2017 [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | 50.00% | ||||||
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Payment Arrangement, Tranche One [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | 50.00% | ||||||
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Payment Arrangement, Tranche Two [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | 50.00% | ||||||
Restricted Stock [Member] | |||||||
Share-based Payment Arrangement, Expense | $ 303,000 | $ 108,000 | $ 777,000 | $ 301,000 | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 4,000,000 | $ 4,000,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 3 years 109 days | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value | 802,000 | 148,000 | $ 4,000,000 | 1,300,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | 368,000 | $ 393,000 | $ 1,600,000 | $ 874,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 224,218 | ||||||
Performance-based Restricted Stock [Member] | |||||||
Share-based Payment Arrangement, Expense | 286,000 | $ 825,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 1,400,000 | $ 1,400,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 1 year 109 days | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 94,247 | 94,247 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 29,604 | 123,851 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $ 2,200,000 | $ 2,200,000 | |||||
Performance-based Restricted Stock [Member] | Minimum [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards | 0.00% | ||||||
Performance-based Restricted Stock [Member] | Maximum [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 188,494 | 188,494 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards | 200.00% |
Note 7 - Share-based Compensa_4
Note 7 - Share-based Compensation - Stock Option Activity (Details) - $ / shares | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | |
Share-based Payment Arrangement, Option [Member] | |||
Outstanding (in shares) | 2,043,402 | ||
Outstanding at beginning of year, weighted average exercise price (in dollars per share) | $ 1.91 | ||
Granted (in shares) | 0 | 0 | |
Granted, weighted average exercise price (in dollars per share) | |||
Exercised (in shares) | (339,237) | ||
Exercised, weighted average exercise price (in dollars per share) | $ 1.83 | ||
Forfeited (in shares) | (3,437) | ||
Forfeited, weighted average exercise price (in dollars per share) | $ 5.69 | ||
Expired (in shares) | |||
Expired, weighted average exercise price (in dollars per share) | |||
Outstanding (in shares) | 1,700,728 | ||
Outstanding at end of year, weighted average exercise price (in dollars per share) | $ 1.92 | ||
Stock options exercisable at year end (in shares) | 1,546,830 | 1,546,830 | |
Stock options exercisable at year end, weighted average exercise price (in dollars per share) | $ 1.89 | ||
Outstanding (in shares) | 1,546,830 | ||
Performance Shares [Member] | |||
Outstanding at beginning of year, weighted average exercise price (in dollars per share) | $ 1.64 | ||
Granted (in shares) | |||
Granted, weighted average exercise price (in dollars per share) | |||
Exercised (in shares) | (135,000) | ||
Exercised, weighted average exercise price (in dollars per share) | $ 1.64 | ||
Outstanding at end of year, weighted average exercise price (in dollars per share) | $ 1.64 | ||
Stock options exercisable at year end (in shares) | 964,997 | 829,997 | |
Stock options exercisable at year end, weighted average exercise price (in dollars per share) | $ 1.64 | ||
Outstanding (in shares) | 964,997 | ||
Outstanding (in shares) | 829,997 |
Note 7 - Share-based Compensa_5
Note 7 - Share-based Compensation - Restricted Stock Activity (Details) - $ / shares | Apr. 01, 2019 | Sep. 30, 2019 |
Restricted Stock [Member] | ||
Outstanding at beginning of year (in shares) | 279,919 | |
Outstanding at beginning of year (in dollars per share) | $ 5 | |
Unvested granted (in shares) | 224,218 | |
Granted, grant date fair value (in dollars per share) | $ 17.68 | |
Vested (in shares) | (106,683) | |
Vested, grant date fair value (in dollars per share) | $ 4.65 | |
Forfeited (in shares) | (26,354) | |
Forfeited, grant date fair value (in dollars per share) | $ 11.60 | |
Outstanding (in shares) | 371,100 | |
Outstanding (in dollars per share) | $ 12.29 | |
Performance-based Restricted Stock [Member] | ||
Outstanding at beginning of year (in shares) | ||
Outstanding at beginning of year (in dollars per share) | ||
Unvested granted (in shares) | 29,604 | 123,851 |
Granted, grant date fair value (in dollars per share) | $ 17.79 | |
Vested (in shares) | ||
Vested, grant date fair value (in dollars per share) | ||
Outstanding (in shares) | 123,851 | |
Outstanding (in dollars per share) | $ 17.79 |
Note 7 - Share-based Compensa_6
Note 7 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Stock compensation expense | $ 654 | $ 383 | $ 1,907 | $ 1,131 |
Research and Development Expense [Member] | ||||
Stock compensation expense | 122 | 65 | 327 | 195 |
Selling and Marketing Expense [Member] | ||||
Stock compensation expense | 141 | 64 | 438 | 202 |
General and Administrative Expense [Member] | ||||
Stock compensation expense | 338 | 195 | 1,016 | 577 |
Cost of Sales [Member] | ||||
Stock compensation expense | $ 53 | $ 59 | $ 126 | $ 157 |
Note 8 - Warrants (Details Text
Note 8 - Warrants (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2019 | Dec. 31, 2018 | |
Class of Warrant or Right, Outstanding | 3,963,505 | 3,963,505 | 4,080,005 |
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 4.33 | $ 4.33 | $ 4.35 |
Class of Warrant or Right, Exercised During Period | 87,500 | 116,500 | |
Class of Warrant or Right, Exercised During Period, Exercise Price | $ 4.75 | $ 4.75 | |
Proceeds from Warrant Exercises | $ 416,000 | $ 553,000 |
Note 10 - Net Income Per Comm_3
Note 10 - Net Income Per Common Share - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Net income attributable to common stockholders | $ 9,316 | $ 1,151 | $ 10,581 | $ 2,094 |
Basic shares used to compute earnings per share (in shares) | 19,735,364 | 17,273,412 | 19,071,722 | 15,529,026 |
Effect of dilutive securities (in shares) | 5,607,748 | 6,383,221 | 5,633,702 | 5,522,193 |
Weighted average diluted shares (in shares) | 25,343,112 | 23,656,633 | 24,705,424 | 21,051,219 |
Basic net income per common share (in dollars per share) | $ 0.47 | $ 0.07 | $ 0.55 | $ 0.13 |
Diluted net income per common share (in dollars per share) | $ 0.37 | $ 0.05 | $ 0.43 | $ 0.10 |
Note 12 - Revenue - Disaggregat
Note 12 - Revenue - Disaggregated Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Net product sales | $ 6,604 | $ 5,293 | $ 19,075 | $ 14,286 |
Regenerative Medicine [Member] | ||||
Net product sales | 3,421 | 2,876 | 9,567 | 7,965 |
Media [Member] | ||||
Net product sales | 6,069 | 5,293 | 18,165 | 14,286 |
Distribution Service [Member] | ||||
Net product sales | 2,613 | 1,887 | 7,943 | 4,621 |
Automated Thawing Products [Member] | ||||
Net product sales | 324 | 699 | ||
Drug Discovery [Member] | ||||
Net product sales | 225 | 276 | 711 | 916 |
Cold Chain Shipping [Member] | ||||
Net product sales | 211 | 211 | ||
BioBanking [Member] | ||||
Net product sales | $ 345 | $ 255 | $ 854 | $ 784 |
Note 13 - Leases (Details Textu
Note 13 - Leases (Details Textual) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2019USD ($) | Sep. 30, 2019USD ($) | |
Operating Lease, Weighted Average Discount Rate, Percent | 6.50% | 6.50% |
Finance Lease, Weighted Average Discount Rate, Percent | 8.10% | 8.10% |
Operating Lease, Weighted Average Remaining Lease Term | 1 year 292 days | 1 year 292 days |
Finance Lease, Weighted Average Remaining Lease Term | 1 year 146 days | 1 year 146 days |
Operating Lease, Cost | $ 160,000 | $ 444,000 |
Operating Lease, Payments | $ 204,000 | $ 576,000 |
Bothell, Washington Headquarters [Member] | ||
Lessee, Operating Lease, Renewal Term | 5 years | 5 years |
Note 13 - Leases - Maturities o
Note 13 - Leases - Maturities of Lease Liabilities (Details) - USD ($) | Sep. 30, 2019 | Jan. 01, 2019 |
2019, operating leases | $ 201,000 | |
2019, financing leases | 4,000 | |
2020, operating leases | 868,000 | |
2020, financing leases | 15,000 | |
2021, operating leases | 556,000 | |
2021, financing leases | 3,000 | |
Total operating lease payments | 1,625,000 | |
Total financing lease payments | 22,000 | |
Less: operating lease interest | (101,000) | |
Less: financing lease interest | (2,000) | |
Total present value of operating lease liabilities | 1,524,000 | $ 1,800,000 |
Total present value of financing lease liabilities | $ 20,000 |
Note 14 - Subsequent Event (Det
Note 14 - Subsequent Event (Details Textual) - USD ($) $ in Thousands | Nov. 12, 2019 | Oct. 02, 2019 | Sep. 30, 2019 | Sep. 30, 2018 |
Payments to Acquire Equity Method Investments | $ 6,000 | |||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 19,932 | |||
Subsequent Event [Member] | Custom Biogenic Systems, Inc. [Member] | ||||
Business Combination, Consideration Transferred, Total | $ 15,000 | |||
Payments to Acquire Businesses, Gross | 11,000 | |||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 4,000 | |||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 15,000 | |||
Business Combination, Contingent Consideration Arrangements, Earn-out Period | 5 years | |||
Subsequent Event [Member] | Sexton Biotechnologies [Member] | ||||
Payments to Acquire Equity Method Investments | $ 1,500 | |||
Equity Method Investment, Ownership Percentage | 18.00% |